# D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice

**Authors:** Yermek Rakhat, Seiya Banno, Dauren Zhantleu, Shin Tsunekawa, Daisuke Yabe, Yutaka Seino, Yusaku Iwasaki, Toshihiko Yada

PMC · DOI: 10.3390/nu18040707 · 2026-02-23

## TL;DR

D-Allulose and oral semaglutide both reduce weight and improve muscle strength in obese mice, but D-Allulose maintains weight loss longer.

## Contribution

D-Allulose shows more persistent weight loss than oral semaglutide in diet-induced obese mice.

## Key findings

- D-Allulose and oral semaglutide both reduce food intake and body weight in the early treatment phase.
- D-Allulose maintains weight loss longer than oral semaglutide after treatment ends.
- Both substances increase muscle strength, but D-Allulose uniquely inhibits orexigenic neurons in the hypothalamus.

## Abstract

Background: Rare sugar D-Allulose, a zero-calorie sweetener, markedly ameliorates obesity. It reportedly stimulates the release of endogenous glucagon-like peptide 1 (GLP-1) to activate vagal afferent and directly influences the neurons in hypothalamic arcuate nucleus (ARH), thus evoking vagal and central nervous routes. D-Allulose can now be produced substantially, being expected for diet therapy. Oral form GLP-1 receptor agonist (GLP-1RA), Oral semaglutide (O-Sema), without injection markedly ameliorates obesity. It evokes only central nervous route. Thus, these GLP-1-based substances utilize common/distinct routes, suggesting common/distinct effects on obesity and related disorders including sarcopenia. To address it, this study precisely compared their effects. Methods: O-Sema and D-Allulose were administered to diet-induced obese mice under identical conditions, equivalent doses, oral gavage, and food/water deprivation. Acute and sub-chronic effects on food intake, body weight and grip strength were measured. Results: Acutely, D-Allulose rapidly and O-Sema slowly reduced feeding. Sub-chronically, D-Allulose and O-Sema profoundly reduced food intake and weight in the early period (0–3 days) of treatment. The weight loss was diminished with O-Sema but maintained with D-Allulose in the late period (4–10 days) and after termination of treatment. D-Allulose and O-Sema increased muscle strength. Mechanistically, D-Allulose and semaglutide similarly activated anorexigenic leptin-responsive neurons while only D-Allulose significantly inhibited orexigenic ghrelin-responsive neurons in ARH. Conclusions: D-Allulose and O-Sema equally elicit weight reduction possibly via the central nervous route including ARH anorexigenic neuron activation. The weight loss is rebounded with O-Sema, while it is maintained with D-Allulose possibly via combined vagal afferent and central nervous routes including ARH orexigenic neuron inhibition. Their optimal use potentially provides precise control of obesity and related disorders.

## Linked entities

- **Proteins:** GCG (glucagon), lepa (leptin a), GHRL (ghrelin and obestatin prepropeptide)
- **Chemicals:** D-Allulose (PubChem CID 441036), semaglutide (PubChem CID 56843331), Oral semaglutide (PubChem CID 56843331)
- **Diseases:** obesity (MONDO:0011122)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Dpp4 (dipeptidylpeptidase 4) [NCBI Gene 13482] {aka Cd26, Dpp-4, THAM}, LDLRAP1 (low density lipoprotein receptor adaptor protein 1) [NCBI Gene 26119] {aka ARH, ARH1, ARH2, FHCB1, FHCB2, FHCL4}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, Glp1r (glucagon-like peptide 1 receptor) [NCBI Gene 14652] {aka GLP-1R, GLP1Rc}, Ldlrap1 (low density lipoprotein receptor adaptor protein 1) [NCBI Gene 100017] {aka ARH2, Arh, Arh1, FHCB1, FHCB2}, Gcg (glucagon) [NCBI Gene 14526] {aka GLP-1, Glu, PPG}, Lep (leptin) [NCBI Gene 16846] {aka ob, obese}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, Ghrl (ghrelin) [NCBI Gene 58991] {aka 2210006E23Rik, Ghr, MTLRP, MTLRPAP, m46}, Pomc (pro-opiomelanocortin-alpha) [NCBI Gene 18976] {aka ACTH, BE, Beta-LPH, Clip, Gamma-LPH, Npp}
- **Diseases:** hyperglycemic (MESH:D006944), physical disability (MESH:D059445), hyperglycemia (MESH:D006943), sarcopenia (MESH:D055948), injury to (MESH:D014947), weight loss (MESH:D015431), diabetes (MESH:D003920), excessive appetite (MESH:D001068), hyperphagia (MESH:D006963), Declined muscle (MESH:D009135), DIO (MESH:D009765), nausea (MESH:D009325), weight gain (MESH:D015430), type 2 diabetes (MESH:D003924), vomiting (MESH:D014839), fat mass loss (MESH:C536030), cardio-metabolic diseases (MESH:D008659)
- **Chemicals:** HEPES (MESH:D006531), sugars (MESH:D000073893), NaCl (MESH:D012965), Chemicals (-), NaHCO3 (MESH:D017693), fat (MESH:D005223), MgSO4 (MESH:D008278), isoflurane (MESH:D007530), fura-2 AM (MESH:C049925), D-Allulose (MESH:C003243), DW (MESH:D014867), Blood Glucose (MESH:D001786), NaOH (MESH:D012972), Glucose (MESH:D005947), fura-2 (MESH:D016257), CaCl2 (MESH:D002122), KCl (MESH:D011189)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** H10 D
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943764/full.md

---
Source: https://tomesphere.com/paper/PMC12943764